Back

The OncoSim-Breast cancer microsimulation model

Yong, J. H. E.; Nadeau, C.; Flanagan, W.; Coldman, A.; Asakawa, K.; Garner, R.; Fitzgerald, N.; Yaffe, M.; Miller, A.; OncoSim-Breast Working Group,

2020-05-24 oncology
10.1101/2020.05.22.20110569
Show abstract

BackgroundThe increasing demand for health care resources requires measures to evaluate the impact of cancer control approaches. A cancer simulation model can help integrate new knowledge to inform clinical and policy decisions. OncoSim-Breast is a breast cancer simulation model. This paper aims to describe the key assumptions in the OncoSim-Breast model and how well it reproduces more recent breast cancer trends and the observed effects in a randomized screening trial. MethodsThe OncoSim-Breast model simulates the onset, growth and spread of invasive and ductal carcinoma in situ tumours. The model combines Canadian cancer incidence, mortality, screening program and cost data to project population-level outcomes. Users can change the model input to answer specific policy questions. Here we report three validation exercises. First, we compared the models projected breast cancer incidence and stage distributions with the observed data in the Canadian Cancer Registry. Second, we compared OncoSims projected breast cancer mortality with the Vital Statistics. Third, we replicated the UK Age trial to compare the models projections with the trials observed screening effects. ResultsOncoSim-Breasts projected incidence, mortality and stage distribution of breast cancer were close to the observed data in the Canadian Cancer Registry and the Vital Statistics. OncoSim-Breast also reproduced the breast cancer screening effects observed in the UK Age trial. InterpretationOncoSim-Breasts ability to reproduce the observed population-level breast cancer trends and the screening effects in a randomized trial increases the confidence of using its results to inform policy decisions related to early detection of breast cancer.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
PLOS ONE
based on 1737 papers
Top 22%
18.0%
2
BMJ Open
based on 553 papers
Top 9%
11.8%
3
PLOS Computational Biology
based on 141 papers
Top 2%
8.8%
4
JCO Clinical Cancer Informatics
based on 14 papers
Top 0.4%
5.0%
5
eLife
based on 262 papers
Top 6%
4.1%
6
Scientific Reports
based on 701 papers
Top 47%
3.1%
50% of probability mass above
7
Cancer Epidemiology, Biomarkers & Prevention
based on 14 papers
Top 0.6%
3.1%
8
Breast Cancer Research
based on 11 papers
Top 0.3%
3.1%
9
British Journal of Cancer
based on 22 papers
Top 1%
3.0%
10
International Journal of Cancer
based on 18 papers
Top 0.7%
2.4%
11
Trials
based on 24 papers
Top 1%
2.0%
12
Cancer Medicine
based on 17 papers
Top 2%
1.9%
13
JAMA Network Open
based on 125 papers
Top 9%
1.9%
14
BMC Research Notes
based on 11 papers
Top 0.1%
1.7%
15
Clinical Cancer Research
based on 22 papers
Top 3%
1.7%
16
PeerJ
based on 46 papers
Top 6%
1.4%
17
BMC Health Services Research
based on 43 papers
Top 3%
1.4%
18
Bulletin of Mathematical Biology
based on 17 papers
Top 1%
1.4%
19
Cancers
based on 57 papers
Top 6%
1.4%
20
JCO Precision Oncology
based on 11 papers
Top 2%
1.4%
21
International Journal of Radiation Oncology*Biology*Physics
based on 13 papers
Top 2%
1.4%
22
BMC Cancer
based on 21 papers
Top 4%
1.3%
23
International Journal of Epidemiology
based on 65 papers
Top 7%
0.9%
24
JMIR Research Protocols
based on 18 papers
Top 3%
0.8%
25
Statistics in Medicine
based on 17 papers
Top 0.7%
0.8%
26
npj Precision Oncology
based on 14 papers
Top 3%
0.8%
27
BMC Medicine
based on 155 papers
Top 24%
0.7%
28
Scientific Data
based on 30 papers
Top 4%
0.7%
29
Annals of Internal Medicine
based on 27 papers
Top 2%
0.7%